Early Metformin Therapy to Delay Menarche and Augment Height in Girls With Precocious Pubarche EDITORIAL COMMENT


Por: Ibañez-Toda L, López-Bermejo A, Díaz-Silva M, Marcos Sala MV and de Zegher F

Publicada: 1 jun 2011
Resumen:
Early and rapidly progressive puberty is a consequence of precocious pubarche (PP) in low-birth weight (LBW) girls. Early menarche (<12 y) in such girls results in an adult stature below target level and in features of the polycystic ovary syndrome (PCOS). A major driving factor in such early maturation is hyperinsulinemic insulin resistance with total, visceral, and hepatic adiposity. Suggestions have been made that early treatment of LBW-PP girls with metformin, an insulin-sensitizing intervention, may normalize their endocrine-metabolic profile away from adolescent PCOS. This open-label, randomized study was designed to investigate whether intervention with metformin starting at an average age of 8 years and continuing for 4 years delays the onset of puberty in PP girls, increases their postmenarcheal stature, reduces adiposity, and/or produces a more favorable endocrine-metabolic profile. A total of 38 LBW-PP girls were randomly assigned to receive daily doses of metformin for 4 years (n = 19) or to remain untreated for 4 years (n = 19). Each subject in both of the groups was followed subsequently without intervention until all the girls reached postmenarcheal age (5 years in control group and 6 years in metformin-treated group). The primary study outcome measures were age at menarche, height, weight, endocrine-metabolic profile (fasting blood insulin, androgens, and lipids), body composition (determined by absorptiometry), abdominal fat (subcutaneous vs. visceral), and hepatic adiposity (determined by magnetic resonance imaging). Girls in both the groups were on average 2 years postmenarche; height gain was less than 2.0 cm per year in both the groups. Menarche was delayed by about 1 year among the girls in the treated group; the age at menarche was 11.4 0.1 years in the untreated group and 12.5 +/- 0.2 years in the metformin group (P < 0.0001). Two years after stopping the therapy, the metformin-treated girls had a leaner body composition (especially less visceral and hepatic fat) and a more favorable endocrine-metabolic profile. These findings show that early metformin treatment at age 8 to 12 years delays menarche in LBW-PP girls and improves their endocrine-metabolic profile. The data suggest that early metformin treatment has the potential to slow, attenuate, or prevent adolescent PCOS.

Filiaciones:
CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, Spain.
Dr Trueta Hosp, Girona, Spain.
Hosp Terrassa, Endocrinol Unit, Terrassa, Spain.
Univ Leuven, Dept Woman & Child, Louvain, Belgium.
CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, Spain
Dr Trueta Hosp, Girona, Spain
Hosp Terrassa, Endocrinol Unit, Terrassa, Spain
Univ Leuven, Dept Woman & Child, Louvain, Belgium
ISSN: 00297828





OBSTETRICAL & GYNECOLOGICAL SURVEY
Editorial
LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, Estados Unidos America
Tipo de documento: Editorial Material
Volumen: 66 Número: 6
Páginas: 350-351
WOS Id: 000294054100012

MÉTRICAS